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X-linked thrombocytopenia (XLT) because it causes severe and
life-threatening bleeding. Lentiviral gene therapy (GT) for WAS
has shown promising results in terms of immune reconstitution.
However, despite the reduced severity and frequency of bleeding
events, platelet counts remain low in GT-treated patients.
Objective: We carefully investigated platelet defects in terms of
phenotype and function in untreated patients with WAS and
assessed the effect of GT treatment on platelet dysfunction.
Methods: We analyzed a cohort of 20 patients with WAS/XLT,
15 of them receiving GT. Platelet phenotype and function were
analyzed by using electron microscopy, flow cytometry, and an
aggregation assay. Platelet protein composition was assessed
before and after GT by means of proteomic profile analysis.
Results: We show that platelets from untreated patients with
WAS have reduced size, abnormal ultrastructure, and a
hyperactivated phenotype at steady state, whereas activation
and aggregation responses to agonists are decreased. GT
restores platelet size and function early after treatment and
reduces the hyperactivated phenotype proportionally to WAS
protein expression and length of follow-up.
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Maryland.proteomic profile with consequent restoration of platelet
ultrastructure and phenotype, which might explain the observed
reduction of bleeding episodes after GT. These results are
instrumental also from the perspective of a future clinical trial
in patients with XLT only presenting with
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Wiskott-Aldrich syndrome (WAS; OMIM 301000) is a severe
X-linked primary immunodeficiency that affects 4 per million
male births, with a life expectancy of less than 15 years in severe
cases.1,2 This syndrome is caused by mutations in the WAS gene
encoding Wiskott-Aldrich Syndrome protein (WASp), a hemato-
poietic specific actin regulator.3,4 Patients with the classical
phenotype are characterized by microthrombocytopenia, immu-
nodeficiency, eczema, and increased susceptibility to autoimmu-
nity and malignancies. Patients presenting with only
microthrombocytopenia without other clinical manifestations
are referred to as having X-linked thrombocytopenia (XLT).5,6
Since its identification, WAS has been described as ‘‘familial
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challenges. Platelet counts in patients range from less than 3,000
up to 70,000 platelets/mL, with amean platelet volume half of that
of healthy donors (HDs).2,9 Bleeding events range from mild skin
petechiae to life-threatening manifestations, such as gastrointes-
tinal and intracranial hemorrhages, which account for about
23% of deaths.10,11
Severe thrombocytopenia often requires supportive treatment,
including platelet transfusions. Splenectomy can be an effective
treatment, especially for patients with XLT without autoimmu-
nity12; however, this treatment carries a significant long-term risk
of sepsis and is therefore not indicated for all patients, especially
if a more definitive treatment is foreseen in the future.9,13 Recently,
new thrombopoietin agonists have been reported to be efficacious
in preventing life-threatening hemorrhagic episodes.14-16
The current curative treatment for WAS is hematopoietic stem
cell transplantation (HSCT) from an HLA-identical donor, which
is available only for a minority of patients. Despite an overall 5-
year survival of 89.1%, significant morbidity and mortality are
still an issue with this procedure, particularly in patients older
than 5 years.17,18 Gene therapy (GT) clinical trials, in which pa-
tients receive autologous CD341 cells transducedwith a lentiviral
(LV) vector encoding humanWASp, are ongoing. Preliminary an-
alyses showed safety and efficacy with improved but not normal-
ized platelet counts and reduced bleeding episodes.19,20 Several
studies have been conducted to elucidate the pathogenesis of
thrombocytopenia in patients with WAS. Defective platelet pro-
duction by megakaryocytes and accelerated peripheral elimina-
tion have been proposed as the underlying cause, highlighting
an unsolved dichotomy.21 Megakaryocytes have been described
to fail both in the maturation step and in proplatelet production.21
Conversely, several articles showed that after normal thrombopoi-
esis, platelets in the periphery are the target of both innate and
adaptive immunity.21 Recently, using a conditional WAS murinemodel lacking WASp only in platelets and megakaryocytes, we
dissected intrinsic versus extrinsic platelet defects, demonstrating
how mutant platelets induce a specific autoimmune response
mediated by macrophages and B cells, leading to
thrombocytopenia.22
Here we performed a detailed analysis of platelet phenotype
and function in patients with WAS before and after LV-GT. Our
data show that platelets isolated from untreated patients with
WAS have abnormalities in ultrastructure and function, as well as
a perturbed proteomic profile and metabolic activity. These
defects significantly improve after GT in correlation with the
restoration of WASp expression in platelets. Overall, this study
provides new evidence of the pathogenic dysregulation of cellular
mechanisms in platelets from patients with WAS, providing
further clarification of the effect of WASp on the structure and
function of platelets compared with data reported thus far in the
literature.21 It is the first study that demonstrates the extent to
which LV-GT is able to correct morphologic and functional
platelet abnormalities in patients with WAS, restoring platelet
morphology, activation, and function and preventing the occur-
rence of bleeding manifestations starting at very early time points
after treatment. These findings will be instrumental also for a
perspective clinical trial targeting patients with XLT in whom
the correction of platelet phenotype in the absence of other
concomitant clinical manifestations is of primary importance
also to prevent life-treating complications that can arise in these
patients with their progression to a more severe phenotype.23METHODS
Experimental design
Data reported in this article were obtained from blood samples from
patients withWAS and HDs. Diagnosis ofWASwas based on clinical findings
and confirmation using genetic analysis. Table E1 in this article’s Online Re-
pository at www.jacionline.org describes the clinical features and analyses
performed for each patient. Details about the experimental design and GT pro-
cedure are described in theMethods section in this article’s Online Repository
at www.jacionline.org and extensively reported elsewhere.19Sample collection
Complete peripheral blood count analysis was performed at Laboraf
(Ospedale San Raffaele, Milano, Italy). Platelet-rich plasma (PRP) was
obtained by centrifuging peripheral blood (Citrate .105M/3.2%, BD Vacu-
tainer; BD, Franklin Lakes, NJ) for 10 minutes at 700 rpm, as previously
described.22 Plasma was collected by centrifuging blood (K2EDTA 7.2 mg,
BD Vacutainer) for 10 minutes at 2000 rpm.Cytofluorimetric staining
Cell suspensions were stained with the following anti-human antibodies:
anti-PAC1 (PAC-1) from BD PharMingen (San Diego, Calif); anti-CD61 (VI-
PL2) from BioLegend (San Diego, Calif); and anti–P-selection (CD62P;
Psel.KO2.3) from Invitrogen (Carlsbad, Calif). Intracellular WASp staining
was performed as previously described24 or by using a purified mouse anti-
humanWASp antibody (Clone 5A5) from BD PharMingen. All the flow cyto-
metric samples were acquired with a FACSCanto II system (BD) and analyzed
with FlowJo software (TreeStar, Ashland, Ore).Electron microscopy
Transmission electron microscopy (TEM) was performed, as previously
described.22 Briefly, PRP was centrifuged for 7 minutes at 3200 3g, and the
pellet was fixed, washed, dehydrated, and embedded in Epon (Sigma, St Louis,
AB
C
FIG 1. Platelet (PLT) counts and WASp expression in HDs and post-GT patients. A, Platelet counts are re-
ported for the first 8 patients enrolled in the TIGET-WAS trial (WAS_1HP to WAS_9HP); measurements
were taken at the defined time points indicated in Table E1. The lower normal limit for HDs (150 3 109/L)
is reported. B, mean platelet volume (MPV) is reported for HDs and patients (WAS_1HP to WAS_9HP) at
the last FU indicated in Table E1. HD values are reported as reference. For patient WAS_7HP, MPV analysis
is available at 4 years after GT instead of 5 years after GT. C,WASp expression is reported in HDs and post-
GT patients in terms of percentages of WASp1 platelets or MFIs on the whole platelet population. Analysis
was performed for research purposes and not for the official case report form. Median values are reported
below the groups analyzed. Statistical analysis in Fig 1, C, was performed by using the Mann-Whitney test.
A P value of less than .05 was considered statistically significant. *P < .05 and ***P < .001.
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scope (Zeiss, Oberkochen, Germany).
To perform whole-mount TEM, a volume of 7 mL of PRP (1 3 106 plate-
lets/mL) was placed on a Formvar/Carbon Coated-Nickel 200 Mesh (Electron
Microscopy Sciences, Hatfield, Pa) for 5 minutes, washed, dried for 20 mi-
nutes, and, without fixation, imaged directly with the LEO 912AB at 80 kV.
Images were analyzed by using ImageJ software (National Institutes of
Health, Bethesda, Md).Platelet staining
Platelet activation was performed, as previously described.22 Briefly, plate-
lets were stained with CD61, CD62P, and PAC1 and then activated with aden-
osine diphosphate (ADP; 0.1 mmol/L to 20 mmol/L; Sigma-Aldrich, St Louis,
Mi) for 15 minutes. Activation is expressed as percentages of CD62P1 or
PAC11 platelets; CD62P/CD61 or PAC1/CD61 mean fluorescence intensity




FIG 2. Platelet (PLT) ultrastructure in pre-GT and post-GT patients. A, TEM images of platelets isolated from
HDs. Several internal structures are depicted in the picture: OCS, mitochondria (Mit), glycogen granules
(Gly), and a-granules (a-gr.). B and C, Representative TEM images of platelets isolated from pre-GT (Fig
2, B) or post-GT (Fig 2, C) patients with WAS. For each post-GT patient, the FU period is indicated as years
after GT (y pGT) or days after GT (d pGT). Images have been acquired with a 2048 3 2048–pixel camera.
Scale bars are shown. S refers to splenectomized patient.
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4 SERENI ET ALIntracellular reactive oxygen species (ROS) production was measured with
the ROS-ID Total ROS/Superoxide detection Kit (Enzo Life Sciences,
Farmingdale, NY), according to the manufacturer’s instructions.PFA-100 test
Platelet aggregation was tested on peripheral blood (Citrate .105M/3.2%,
BD Vacutainer in a PLT Function Analyzer 100 [PFA-100, Siemens, Berlin,
Germany]) by using ADP-collagen cartridges, according to the manufac-
turer’s instructions. Hematocrit values of analyzed patients were in the range
of normality. A standard curve was generated to account for differences in
platelet counts, as described in the Methods section in this article’s Online
Repository.ELISA tests
ELISA kits to evaluate concentrations of soluble P-selectin (sCD62P),
soluble CD40 ligand (sCD40L), and B cell–activating factor (BAFF) in
plasma were purchased from R&D Systems (Minneapolis, Minn) and usedaccording to the manufacturer’s instructions; sCD62P and sCD40L levels
were normalized for platelet counts and expressed as nanograms per mL per
1000 platelets. Von Willebrand factor (vWF) collagen binding ability was
measured by using the ‘‘ASSERACHROM VWF:CB’’ ELISA Kit from
Diagnostica STAGO (Asnieres sur Seine, France).Sample preparation and proteomics analysis
As previously described,22 pellets of the purified fraction of platelets were
collected from HDs and patients with WAS before and after GT and stored at
2808C. Detailed descriptions of proteomic analysis, data processing, and
interaction network reconstruction are described in the Methods section in
this article’s Online Repository.Statistical analysis
All results are expressed as means 6 SDs, unless stated otherwise.
Statistical tests used are specified in the Methods section in this article’s On-
line Repository.
AB
FIG 3. Recovery of platelet (PLT) size after GT. Size of platelets isolated from patients before and after GT
(WAS_1HP to WAS_9HP) was measured by using TEM. Size is expressed as area (in square micrometers;
A) or perimeter (in micrometers; B). Each dot represents a single platelet. Splenectomized untreated pa-
tients with WAS are indicated with S; adult patients are indicated with a. Each HD analyzed is reported in
the box. Median values of area and perimeter are reported above HDs and untreated patients with WAS.
Linear mixed-effects models have been applied to evaluate whether patients with WAS after GT and HDs,
measured several times, were different in terms of platelet area and perimeter. Logarithmic transformation
has been applied to both outcomes. Along with the fixed effect of group, subject-specific random effects
have been specified in the model. For both outcomes, we did not find a significant group effect (see tables
below graphs in the figure).
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FIG 4. Expression of platelet (PLT) activation markers in patients with WAS before and after GT. A and B,
Analysis of activation marker surface expression in platelets at steady state in untreated patients with
WAS/XLT (Fig 4, A) or post-GT patients (Fig 4, B). CD62P or PAC1 expressions are reported as percentages
on total platelets or asMFI ratio. C,Correlation between percentages of CD62P1 platelets and percentages of
WASp1 platelets (left panel) and WASp MFI (right panel), respectively. D, Levels of sCD62P in plasma of
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WASp expression ameliorates the platelet
compartment
We analyzed platelet phenotype and function in a cohort of
patients with WAS/XLT, including patients who received either
LV GT combined with reduced-intensity conditioning or HSCT.
Platelet counts measured in 8 patients (WAS_1HP to
WAS_9HP) treated with GT (see Table E1) increased after treat-
ment in all patients but remained less than normal values (Fig 1,
A). Importantly, mean platelet volume, which was not measurable
in untreated patients, was in the normal range at the last follow-up
(FU) after GT in all patients analyzed (7.4-10.9 fL; Fig 1, B).
The percentage of WASp1 platelets ranged between 3% and
28% before GT (F. Ferrua and M. P. Cicalese et al, unpublished
data) and increased up to a median of 76.1% in patients after
GT with an FU of less than 2 years and 91.2% in patients with
an FU of longer than 2 years (Fig 1, C). In line with this, WASp
MFI was calculated in the whole platelet population and still re-
mains very low in samples isolated from patients after GT at up
to 2 years of FU compared with control subjects (Fig 1, C), sug-
gesting a suboptimal expression of the protein in this cellular
subset.Restoration of platelet ultrastructure and size after
GT
To evaluate ultrastructural morphology, we performed TEM
analysis on the whole platelet population isolated from HDs and
patients with WAS (4 before and 8 after GT). Of note, post-GT
samples are composed of a heterogeneous population of WASp1
and WASp2 platelets.
We analyzed the distribution of a-granules, glycogen granules,
vacuoles, the open canalicular system (OCS), and mitochondria
in platelets isolated from patients with WAS and HDs (Fig 2, A).
Platelets isolated from pre-GT patients showed severe alterations
in ultrastructure, with a reduction in granule content, as already
reported,25 and an increased number of vacuoles and enlargement
of theOCS (Fig 2,B). The features have been described as signs of
platelet activation.26 Conversely, normal granule content and
OCS structure were observed in platelets obtained from all
post-GT patients (Fig 2, C).
Whole-mount TEM showed a reduction of electron-dense
granule (d-g) content in patients with WAS (mean, 3 d-g/platelet)
compared with the reference range for HDs (4-8 d-g/platelet).27
The number of granules normalized after GT (mean, 5.6 d-g/
platelet; see Fig E1 in this article’s Online Repository at www.
jacionline.org).
Platelet area and perimeter were also measured by using TEM
images. Statistical analyses were not applied because of the low
number of untreated patients withWAS analyzed. At a descriptive
level, median values of platelet perimeter (in micrometers) andpatients before and after GT. E, Correlations between
panel) or percentages of WASp1 platelets (right panel
or BAFF (Fig 4, G) in plasma of patients before and aft
depicted as circles, and post-GT samples are depicted
the Mann-Whitney unpaired t test or parametric unpa
GT versus post-GT was used (multiplicity correction
mixed-effects models have been applied to evaluate wh
than 3 years differed from HDs (details are provided
applied to all the outcomes, except the MFI of CD62P.
*P < .05, **P < .005, ***P < .001, and ****P < .0001.area (in square micrometers; Fig 3, A and B) were lower in non-
splenectomized untreated patients (WAS13_HP andWAS_16HP)
compared with those in control subjects. Platelets isolated from
splenectomized untreated patients (WAS10_HP andWAS_14HP)
were more similar to those from control subjects, which is in line
with literature describing amelioration of platelet size and counts
after splenectomy.13,28 Linear mixed-effects models have been
applied to evaluate whether patients with WAS after GT and
HDs, measured several times at different time points, were
different in terms of platelet area and perimeter. Logarithmic
transformation has been applied to both outcomes to linearize
the relationship. Along with the fixed effect of group, subject-
specific random effects have been specified in the model. For
both outcomes, we found that all patients with WAS after GT
were comparable with HDs (no significant group effect, Fig 3).Normalization of hyperactivated phenotype in post-
GT patients
To assess whether dysmorphic platelet ultrastructure could be
associated with dysregulated activation at steady state, we
evaluated the expression of P-selectin (CD62P) and the activated
form of integrin aIIbb3 (PAC1). Levels of both activation
markers were greater in platelets isolated from untreated patients
with WAS than those from HDs (Fig 4, A), confirming our previ-
ous findings in a smaller cohort of patients.22 Post-GT patients
were analyzed at different time points after treatment (see Table
E1) and clustered into 3 groups according to the duration of FU.
Linear mixed-effects models were applied for each parameter
and analyzed to assess differences between patient groups and
HDs. In particular, a random intercept model has been specified
by including subject-specific random effects in the model.
Logarithmic transformation was applied to all outcomes, except
the MFI of CD62P.
Only patients with less than 1 year of FU had significantly
greater percentages of CD62P1 compared with HDs (P5 .0184).
Conversely, the proportion of PAC11 platelets and the MFI of
both markers were significantly greater in all patients analyzed
when compared with those of control subjects (Fig 4, B, and
see Table E2 in this article’s Online Repository at www.
jacionline.org). However, expression of thesemarkers on platelets
isolated from patients with FUs of longer than 3 years were lower
compared with that seen in patients with shorter FUs, suggesting a
progressive amelioration of the phenotype.
Because of the low number of biological samples, data
obtained from patients with an FU period of between 1 and
3 years were not statistically analyzed. At a descriptive level,
mean values of CD62P and PAC1 expression were intermediate
between those of the group with shorter and the group with longer
FUs. Interestingly, the percentage of CD62P1 platelets found at
steady state in post-GT patients inversely correlated with thesCD62P plasma levels and total platelet counts (left
) are reported. F and G, Levels of sCD40L (Fig 4, F)
er GT are shown. In Fig 4, D-F, pre-GT samples are
as squares. For statistics, in Fig 4, A, D, F, and G,
ired t test versus HDs and the paired t test for pre-
on P-value has been applied). In Fig 4, B, linear
ether patients with FUs of less than 1 year or longer
in Table E2); logarithmic transformation has been




FIG 5. Platelet (PLT) functionality recovers after GT. A and B, Platelet activation in untreated patients with
WAS/XLT (Fig 5, A) and post-GT patients (Fig 5, B) is reported as the percentage of CD62P1 platelets (left
panels) or PAC11 platelets (right panels) after ADP stimulation (mean6 SEM). C, CTs, asmeasured by using
the PFA-100 device, are reported for different platelet counts from HDs (pink curve) as the standard curve. In
the graph each patient analyzed is shown along with the frequency of WASp1 platelets (in red), when avail-
able. N.A., Not available. D, Plasma level of collagen-bound vWF (as a percentage) evaluated by using an
ELISA in patients who underwent the PFA-100 test. Normal ranges for HDs are reported. For statistics, in
Fig 5, A and B, linear mixed-effects models to evaluate the effect of group and of ADP concentration, along
with their interaction, have been applied. We allow for a different dose-response relationship depending on
the concentration level itself by defining a binary variable indicating whether the ADP dose was low (range,
0.1-20 mm) or high (range, 100-20,000 mm). A 3-way interaction model including subject-specific random ef-
fects (Fig 5, A) and nested random effects (Fig 5, B), thus accounting for subject-specific effect and for mul-
tiple evaluations of the same subject at different FU visits, was applied (details are provided in Table E3).
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platelets.
Consistently, all patients showed significantly lower plasma
levels of sCD62P after GT versus before GT (Fig 4, D). This
decrease inversely correlates with platelet counts and WASpexpression (Fig 4, E). Post-GT patients also had lower plasma
concentrations of sCD40L compared with pre-GT patients
(Fig 4, F) and normalization of serum BAFF levels, 2 factors
implicated in autoreactive B-cell survival and autoimmunity
(Fig 4, G).
TABLE I. Samples analyzed by proteomics
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aggregation on stimulation
Activation and aggregation were tested in untreated and GT-
treated patients with WAS to evaluate whether GT restores
platelet function along with phenotype. It should be noted that
because of technical limitations, we were not able to sort WASp1
and WASp2 platelets without affecting viability and function
because all samples from post-GT patients contained a heteroge-
neous population of WASp1 and WASp2 platelets.
To evaluate platelet activation in response to agonist stimula-
tion, we used increasing ADP doses. Linear mixed-effects models
were applied to evaluate the effect of group (patients withWAS vs
HDs) and that of the ADP concentration, along with their
interaction, on both CD62P and PAC1 expression. Cubic trans-
formed and raw data were considered when modeling the 2
outcomes, respectively. Moreover, we allowed for a different
dose-response relationship depending on the concentration level
itself by defining a new binary variable, indicating whether the
ADP dose was low (range, 0.1-20 mm) or high (range, 100-
20,000 mm). Hence we finally specified a model with a 3-way
interaction, including subject-specific random effects.
In terms of CD62P expression, platelets isolated from both
untreated patients withWAS/XLTandHDs showed a significantly
larger response when stimulated with high compared with low
doses of ADP (P <.0001). Additionally, we found a positive effect
of ADP concentration on marker expression within the low dose
ranges (<_20 mmol/L) versus a slightly negative effect at greater
doses (>_100 mmol/L). A negative group effect on CD62P expres-
sion was observed in patients with WAS compared with control
subjects, and only very high doses of ADP were able to induce
expression of CD62P more comparable to those seen in healthy
control subjects (significant 3-way interaction term, see Table
E3 in this article’s Online Repository at www.jacionline.org).
Conversely, no significant group effect was found in PAC1
expression, the value of which was found to be comparable in pa-
tients with WAS and control subjects. We only found a positive
effect of the ADP concentration at low doses, which became
slightly negative for high ADP dose ranges (Fig 5, A, and see
Table E3).
Significantly greater expression of CD62P on platelet surfaces
with high compared with low ADP doses was also found in post-
GT patients (P < .0001). Conversely to patients with WAS/XLT,
post-GT patients showed comparable levels of CD62P on platelet
surfaces. When analyzing PAC1 percentages, only patients with
FUs of less than 1 year had significantly greater values of theoutcome than HDs (P5 .0491); this effect is greater at high con-
centrations (P 5 .0079). For both outcomes, we found a positive
effect of ADP concentration at lower ranges and a slightly nega-
tive effect at high ranges (Fig 5, B, and see Table E3). In these
models nested random effects were specified to account for
subject-specific effect and for the fact that some subjects were
evaluated multiple times at different FU visits. Cubic transforma-
tion was applied to model data on PAC1 expression, whereas raw
data were used as input for the linear mixed-effects model for
CD62P.
Platelet aggregation was tested in vitro by using the PFA-100
System, which mimics a vascular injury and measures platelet
adhesion and aggregation in terms of capillary tube closure times
(CTs; in seconds) using collagen/ADP cartridges. A standard
reference curve was generated from HD samples (n 5 18), plot-
ting platelet counts versus CTs on collagen/ADP stimulation
(Fig 5, C). Seven post-GT patients and 1 post-HSCT patient
with WAS were tested. Platelet aggregation in response to ADP
was comparable with that seen in HDs in the majority of the pa-
tients (Fig 5, C, and see Table E4 in this article’s Online Reposi-
tory at www.jacionline.org). A prolonged CT (>300 seconds,
machine detection limit) was observed with samples from 2
post-GT patients with very low platelet counts, although no sig-
nificant bleeding occurred in these patients after GT. Conversely,
samples from the 2 untreated patients with WAS/XLT analyzed
showed disturbed aggregation in response to ADP with a CT of
greater than 300 seconds (Fig 5, C, and see Table E4).
Plasma levels were measured to exclude that CT values could
have been influenced by vWF concentration. All patients
analyzed with the PFA-100 system, either untreated or after GT,
had vWF plasma levels within the normal range for HDs (Fig 5,
D), suggesting that differences in platelet aggregation were not
due to abnormal glycoprotein Ib/vWF–dependent signaling.Analysis of platelet proteomic profiles
Proteomic analysis was performed on 3 patients before and 4/
5 years after GT in parallel with 3 adult HDs to identify putative
molecular pathways causative of altered platelet phenotype and
function in the absence of WASp (Table I).
More than 1315 proteins were identified (see Table E5 in this
article’s Online Repository at www.jacionline.org), and 372
were shared among the 3 analyzed groups (corresponding to
28.3% of total proteins; see Fig E2, A and B, in this article’s On-
line Repository at www.jacionline.org). Linear discriminant anal-
ysis (LDA) was applied to identify differentially expressed
proteins; 255 of 1315 proteins presenting an F-ratio of 3.5 or
greater and a P value of .05 or less were extracted as descriptors
(see Table E6 in this article’s Online Repository at www.
jacionline.org). Hierarchical clustering of identified descriptors
showed that post-GT patients had an intermediate profile between
HDs and pre-GT patients in terms of protein composition and
expression (see Fig E2, C).
Selected descriptors were plotted into a Homo sapiens protein-
protein interaction network to evaluate differences in protein
pathway expression between patients and control subjects (see
Fig E3 in this article’s Online Repository at www.jacionline.
org). The majority of identified protein networks were downregu-
lated in platelets isolated from samples from pre-GT patients
compared with control samples and ameliorated after GT. We
FIG 6. Protein expression per functional cluster in HDs and patients with WAS before and after GT.
Enrichment of main functional categories of low (blue) and high (red) abundant proteins (see Fig E2) in pre-
GT patients, post-GT patients, and HDs. Bubble size is indicative of the number of proteins involved in each
pathway. Proteins have been classified into 3 groups: platelet function proteins, metabolism-related pro-
teins, and immune-related proteins.
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metabolism, and immune-related proteins (Fig 6).
All proteins involved in cytoskeletal rearrangements,
comprising actin and its interactors (actinin, dynactin, nonmuscle
myosin, tropomyosin, Arpc2/3 complex, cofilin, vinculin, and
filamin A), were downregulated in pre-GT samples, whereas their
expression was partially restored in post-GT patients.
In comparison with pre-GT samples, samples isolated from
post-GT patients showed an increased expression of (1)
membrane integrins and their regulators (integrin-linked pro-
tein kinase and fermitin family homolog 3), (2) proteins
involved in wound healing and platelet plug formation(PECAM1, TREML1, GPIBB, vWF, and PF4), and (3)
proteins implicated in vesicle transport, especially clathrin-
mediated transport (CLTC, PICALM, and AP1B1).
A second major group of proteins found to be downregulated in
pre-GT patients and partially restored after GT treatment were
linked to lipid and carbohydrate metabolism (LDHB, ALDOA,
GAPDH, HK1, and PYGB), fuel for glycolysis, and mitochon-
drial oxidative phosphorylation. Downregulation of proteins
involved in lipid metabolism in pre-GT samples can lead to (1)
decreased processing of fatty acids and fuel for mitochondrial
respiration and (2) lower production of platelet function media-
tors, such as thromboxane A2 and phosphatidylinositol.
AB
FIG 7. Oxidative stress and ROS in HDs and patients with WAS before and after GT. A, Schematic represen-
tation of expression of proteins involved in ROS regulation as identified with proteomics. Color code (based
on normalized SpC) indicates protein expression levels in HD, pre-GT, and post-GT samples. B, Flow cyto-
metric evaluation of ROS production in resting platelets (PLTs) in HDs (n5 5), untreated patients with WAS/
XLT (n 5 2), and post-GT patients (n 5 6).
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immune-related proteins, such as different variable regions of
immunoglobulin heavy and light chains; constant regions of IgM,
IgG4, and IgG2 heavy chain; and complement factors.
Using the proteome remodeling index (see Figs E3 and E4 in
this article’s Online Repository at www.jacionline.org), we iden-
tified proteins of which the perturbed expression in pre-GT sam-
ples (higher or lower compared with control values) was restored
to normal levels in post-GT patients (see Table E7 in this article’s
Online Repository at www.jacionline.org); these descriptors have
been filtered for statistical significance and reported in the
protein-protein interaction network (see Fig E3). The majority
of the proteins that showed normalized expression after GT
were cytoskeleton-related proteins, such as actin B and its regula-
tors, integrins, and surface glycoproteins.
To evaluate whether the dysregulated protein expression found
in the absence of WASp could correspond with a reversion in the
topological importance of proteins within different networks, we
identified the most important hubs present in platelets isolated
before and after GT (see Table E8 in this article’s Online Repos-
itory at www.jacionline.org). The term ‘‘hubs’’ refers to proteins
with greater numbers of protein connections within the cell, sug-
gesting their topological and biological relevance.29 Almost all
the hubs identified in HDs were also found in post-GT samples
but not in pre-GT samples; conversely, all the hubs found in
pre-GT samples were not present in HDs or post-GT samples.
The results suggest that the protein expression changes observed
in WASp2 platelets are associated with dysregulation of cellular
and signal transduction. Indeed, we observed a different pattern of
proteins involved in signal transduction in WASp-deficient plate-
lets comprising signal transducer and activator of transcription 3
(STAT3) and high-mobility group box 1 (HMGB1) instead ofGRB2, LYN kinase, and integrin-linked protein kinase,30,31
which are found in HD samples.ROS signaling is dysregulated in the absence of
WASp
Using proteomics, we identified several proteins involved in
regulation of reactive oxygen species (ROS) production and
degradation (Fig 7, A, and see Table E6). In pre-GT samples
different scavenger enzymes, such as glutathione peroxidase 1
(GPX1), glutathione-S-transferase P1 member, and superoxide
dismutase 2 (SOD2), were downregulated. Of note, lower expres-
sion of GPX1 is in line with upregulation of SELENBP1, which
has been proposed to negatively regulate GPX1 activity.32
Conversely, other antioxidant enzymes, such as glutaredoxin,
peroxiredoxin-2, and catalase, were found to be overexpressed
in pre-GT patients (Fig 7, A) and normalized in post-GT samples.
In line with the dysregulated expression of ROS-related enzymes,
we found that platelets isolated from untreated patients withWAS
produce greater quantities of ROS in resting conditions than those
from HDs, whereas ROS production in post-GT patients was
much lower (Fig 7, B).DISCUSSION
GT has been recently proposed as a potentially curative
treatment for a variety of genetic diseases. WAS, a monogenic
primary immunodeficiency affecting only hematopoietic cells,
was considered an excellent candidate for GT. Although alloge-
neic HSCT still remains the gold standard treatment, different GT
clinical trials with LV vectors are ongoing in Europe
(NCT01515462 and NCT01347242) and the United States
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tients received, after a reduced-intensity conditioning regimen,
autologous CD341 cells transduced with LV carrying the
sequence of human WAS cDNA driven by the endogenous pro-
moter.19 Although platelet counts increase in the majority of pa-
tients treated with GT, complete restoration of platelet counts
remains an issue. Despite the overall success of HSCT, the stan-
dard of care for WAS, reconstitution of platelet numbers, is one
of the major challenges. Platelet counts increase significantly or
normalize after HSCT compared with GT, but a complete restora-
tion of platelet numbers strictly depends on the degree of myeloid
chimerism, even in previously splenectomized patients.17,18,33,34
Full chimerism has not been obtained in GT trials because of
the reduced-conditioning regimen. However, the risk of
transplant-related toxicity and the occurrence of clonal domi-
nance have always discouraged the use of a more intensive condi-
tioning regimen to achieve better myeloid engraftment or use of a
stronger promoter.35
The clinical analysis conducted on the first 8 patients treated in
the current TIGET-WAS clinical trial showed a significant
increase in platelet counts in all patients at 1 year after GT in
the range of mixed-myeloid chimerism after HSCT. This finding
was stable over time and accompanied by reduction of bleeding
events and platelet transfusion independence (F. Ferrua, M. P.
Cicalese, et al, unpublished data). Of note, the presence and/or
persistence of anti-platelet autoantibodies has been observed in
some treated patients, without any direct correlation with platelet
counts (data not shown). However, because the tests used to
evaluate the presence of these autoantibodies do not provide a
titer or specificity indication, no definitive conclusion regarding
the effect of these autoantibodies on platelet reconstitution can be
drawn thus far.
Although clinical benefits in terms of immunologic reconsti-
tution have been reported in those patients, no in-depth evaluation
of platelet function in GT-treated patients has ever been
performed. Furthermore, this analysis could provide relevant
information, particularly from the perspective of a future clinical
trial in patients with XLT.
Here we demonstrate that patients with untreated WAS have
smaller and dysmorphic platelets compared with healthy subjects.
Normalization of platelet size and restoration of ultrastructure
were found in GT-treated patients.
In terms of phenotype, levels of both CD62P, which is involved
in phagocyte-mediated platelet elimination,36-41 and CD40L,
platelets of which are the major source in circulation42 and which
is implicated in autoimmune induction,43-45 were found to be
increased at steady state in pre-GT patients. In line with this,
plasma levels of BAFF, a cytokine that sustains autoreactive B
cells, were increased before GT and normalized after treatment.
Consistent with the greater expression of a-granule–derived acti-
vation markers (CD62P and CD40L), also aIIbb3 integrin activa-
tion (PAC1) was increased in patients with untreated WAS and
normalized after therapy.
Steady-state hyperactivation in platelets isolated from un-
treated patients or at early time points after GT might be due to
(1) a general inflammatory state consequent to impaired antigen
clearance; (2) a decreased ATP level that hampers maintenance of
a proper Ca21 and ion balance, thus preventing activation in cir-
culation; (3) increased ROS production, which can in turn activate
platelets; and (4) high sCD40L levels in circulation, which can
activate platelets in an autoamplification loop.46 Also, plateletsisolated from pre-GT patients had lower metabolic activity, as
indicated by downregulation of many proteins involved in carbo-
hydrates and lipid processing. This might lead to decreased ATP
production and increased senescence, as also suggested by previ-
ously observed greater phosphatidylserine exposure in WASp2
platelets both in murine and human samples.22,47
In particular, endogenous platelet-derived ROS or exogenous
ROS produced under inflammatory conditions, which can be
present in patients with WAS, might influence platelet function48
by decreasing platelet reactivity to stimuli49,50 and amplifying the
activation loop of sCD40L.51 Moreover, platelets express several
receptors for complement components, mediating activation of
both classical and alternative complement pathways that can in
turn activate platelets.52
Platelet function has been found to be defective in patients with
untreated WAS. Using proteomics, we found that WASp2 plate-
lets showed decreased levels of integrins, signal molecules, and
vesicle-transport related proteins. Dysregulated expression of
these proteins associated with decreased metabolic activity indi-
cates an intrinsic defect of platelet activity and function in the
absence ofWASp. In line with this, WASp2 platelets do not prop-
erly respond to ADP in terms of CD62P expression, reflecting
exhaustion, deregulation of vesicles and granule transport, and
decreased signal transduction. On the other hand, we observed
that inside-out signaling leading to integrin affinity maturation
(evaluated by PAC1 binding) occurs normally in pre-GT patients,
confirming previous findings.53 However, the outside-in integrin
signal, which triggers intracellular events resulting in platelet ag-
gregation,54 was found to be defective, corroborating the nonre-
dundant role of WASp in regulating late events of platelet
function.21 In post-GT patients both platelet activation and aggre-
gation were comparable with that in control subjects.
Topological analyses showed that inWASp2 platelets, intracel-
lular signaling mainly involves the proteins STAT3 and HMGB1,
which are likely to counteract the downregulation of many mole-
cules involved in classical signal transduction pathways. STAT3
was recently described to act as a protein scaffold in proinflamma-
tory cytokine IL-6–mediated platelet activation, linking platelet
hyperactivity to inflammation.55 HMGB1 has been widely
described as amediator of platelet function56 inducing a paracrine
and autocrine activation loop.57
In conclusion, our study demonstrates thatWASp2 platelets are
dysfunctional andmore susceptible to peripheral elimination. The
absence ofWASp in platelets leads to a general downregulation of
protein expression and reorganization of protein hierarchy in
signal transduction. These events are associated with the activated
phenotype in terms of surface markers at steady state, along with
defective platelet function in terms of activation and aggregation
after stimulation. The activation state can induce increased senes-
cence, contributing to their peripheral elimination. In line with
this, splenectomized patients show increased platelet counts
without life-saving treatment. GT is able to restore protein expres-
sion and platelet function. Bleeding protection is likely mediated
byWASp1 platelets, which, although reduced in number, are able
to exert their function according to WASp expression.
Our data highlight novel mechanisms that render WASp-
deficient platelets more activated and susceptible to their turnover
and elimination. These defects are present in patients with
untreated WAS/XLT, irrespective of the type of mutation,
confirming that the absence of WASp in platelets is per se suffi-
cient to induce thrombocytopenia in all patients and confirming
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tients with XLT who can easily progress to more severe forms
with substantial risk of severe disease-related complications.23,58
Furthermore, we demonstrate that despite platelet counts remain-
ing less than normal, their ultrastructure, activation, and function
dramatically improve after GT treatment, conferring protection
from bleeding events and platelet transfusion independence.
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Key messages
d This first long-term FU study of platelet reconstitution in
patients with WAS treated by using LV GT demonstrates
protection from bleeding.
d GT restores the phenotype, function, and proteomic pro-
file of platelets early after treatment and stably over time.
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